The Lancet Respiratory Medicine
@LancetRespirMed
Followers
26K
Following
563
Media
2K
Statuses
5K
A unique and international medical journal for respiratory and critical care specialists.
Joined March 2014
We are a world-leading respiratory medicine and critical care journal. While a partial measurement of our impact, we are pleased to share our Impact Factor of 38·7 and CiteScore of 87·1.
1
0
7
Case Report: Pathological findings of #COVID19 associated with #ARDS. Including histological findings of lung, liver, and heart tissue. Provides new insights into the #pathogenesis of #SARSCoV2-related #pneumonia. #coronavirus
19
577
682
NEW Series Paper—A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe #COVID19 . From Prof Dennis McGonagle & colleagues
4
210
465
NEW Series paper—The #COVID19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. From Ignacio Rubio & colleagues
2
208
441
To mark 100 years since the 1918 influenza pandemic, we look at progress made since and ask where now? #influenza100 #pandemicflu #1918flu #influenza1918 - register for free access our most highly cited papers on #pandemicflu
3
133
368
Awake prone positioning of pts w/ hypoxaemic respiratory failure due to #COVID19 reduces incidence of treatment failure & need for intubation w/o any signal of harm. Meta-trial from the Awake Prone Positioning Meta-Trial Group
4
166
333
Where do we stand in the fight against #TB? The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the #EndTB era #LancetTB #WorldTBDay @M_Raviglione @ucl
1
111
306
Marking the #1918flu pandemic we're sharing #influenza content including our Spotlight on seasonal and pandemic flu #influenza100, @isirvAVG. Register for free access to The Lancet journals’ most highly cited papers on #pandemicflu
1
43
208
#Dexamethasone is associated with a substantial reduction in duration of mechanical #ventilation and all-cause 60-day #mortality in patients with #ARDS . New RCT from Jesús ViIlar and colleagues
7
153
217
NEW Viewpoint—The Berlin definition of #ARDS: should patients receiving high-flow nasal oxygen be included?. From Prof Michael Matthay & colleagues
1
91
209
NEW Research—Past #COVID19 infection does not fully protect young people against reinfection. Study from Prof Stuart Sealfon & colleagues
2
158
195
NEW Research— Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early #COVID19 . RCT from Mona Bafadhel & colleagues
4
104
166
#Asthma and #immunology: a call for papers for AAAAI! See full details of the papers we're seeking, and how to submit:
2
61
159
NEW Comment—Rational use of face masks in the #COVID19 pandemic. S Feng et al compare face mask use recommendations by different health authorities & call for governments and public health agencies to make rational recommendations on appropriate use
6
147
169
NEW Research—Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with #COVID19. LIVE-AIR trial from Prof Zelalem Temesgen & colleagues
15
64
156
NEW research: Awake prone positioning is feasible and improves oxygenation in patients with respiratory failure due to #COVID19-related #pneumonia. From Giuseppe Foti & colleagues
3
91
147
NEW Series paper—Respiratory sequelae of #COVID19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation. From @SallySingh_ and colleagues The first in a Series of three papers about #PASC #longCOVID
9
86
145
Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study #LIVES2018 #ESICM2018
1
60
139
NEW: Clinical course and outcomes of critically ill patients with #SARSCoV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study #COVID19 #Coronavirus
3
120
132
In patients with mild-to-mod #COVID19 managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death. Read the ATOMIC2 trial here being presented at #ECCMID2021 by lead author Tim Hinks @HinksLab
5
110
137
#Asthma #Immunology Call for papers for #AAAAI2019 #AAAAI Details, incl how to submit available here -->
0
50
124
Send us your respiratory medicine and critical care research. We are looking for research that will change clinical practice or current thinking for our #ERS special issue #RespiratoryHealth #CriticalCare.#RespiratoryMedicine
5
88
127
Send us your high-quality research on #CysticFibrosis for our @ECFSConference CF special issue.
2
55
122
NEW Health-Care Development: #Tracheostomy in the #COVID19 era: global and multidisciplinary guidance. From Prof David J Feller-Kopman & colleagues
4
66
123
Post-acute sequelae of #COVID19: a growing public health crisis on a global scale that demands a focused, well-resourced, and patient-centred response. Find out more in a new @LancetRespirMed Series #PASC #longCOVID #postCOVID
12
65
112
Our April issue includes a new phase 1 #RandomisedControlledTrial of a novel #TB #vaccine. Free to view with registration. #WorldTBDay #LancetTB @satviuct2017 @AfricanVaccine
0
21
95
NEW Research—Continued enteral nutrition until extubation in critically ill patients in the ICU is a practice that could be safe to implement and be associated with potential benefits. Read the trial from Mickaël Landais & colleagues here: . #SCCM2023
2
45
108
Correspondence regarding patients with #hypertension and #diabetes mellitus and #COVID19 from Michael Roth and colleagues .(1/4).
6
58
104
Effectiveness of WHO’s pragmatic screening algorithm for.child contacts of #tuberculosis cases in resource-constrained.settings #WorldTBDay #LancetTB @StanfordMed
0
23
101
See an Original Investigation from @JAMA_current on the definition of post-acute sequelae of #SARSCoV2 infection And the first paper in a @LancetRespirMed Series on the post-acute sequelae of #COVID19 #PASC #longCOVID #postCOVID
0
53
103
NEW Comment: F Taccone et al on hydroxychloroquine & critically ill #COVID19 pts . “Whether antimalarial drugs could be effective in changing the disease course in pts with severe COVID-19—in particular, in cases requiring ICU admission—remains unknown"
1
71
102
NEW Research—Characterisation of the first 250 000 hospital admissions for #COVID19 in Brazil. From Otavio Ranzani & colleagues
0
26
98
NEW Research—In community-treated patients, the effect of colchicine on #COVID19-related clinical events was not significant. The COLCORONA study from Prof Jean-Claude Tardif & colleagues
3
58
98
On #WorldPneumoniaDay, Stefano Aliberti and colleagues call for the establishment of an International Pneumonia Network to improve awareness and funding for #pneumonia @AlibertiStefano @PneumoniaDay #StopPneumonia #WPD2018
2
43
91
The #cytokinestorm in #COVID19: "Targeting thrombin, coagulation factor Xa, or PAR-1, might be an attractive approach to reduce #SARSCoV2 microthrombosis, lung injury, and associated poor outcomes". NEW Correspondence from R Jose & A Manuel
1
73
97
Interstitial Lung Disease 2021. A Series of papers on #ILD from @TheLancet and @LancetRespirMed, published to coincide with #ERS2021, is now live #ERSCongress @EuroRespSoc @KerriBerriKerri
1
26
98
Long-term developmental effects of withholding parenteral nutrition for 1 week in the #paediatric intensive care unit: 2-year follow-up of PEPaNIC Register now for free @LancetRespirMed & @TheLancet content from #ERSCongress
3
36
92
NEW Research—Hospitalised #COVID19 patients in UK who received inhaled form of interferon beta-1a were more likely to recover & less likely to develop severe symptoms than those who received placebo: phase 2 RCT.
2
37
94
There is an urgent need for unification of terminology for the sequelae of #SARSCoV2 infection to ensure that research is directed towards and translated into interventional trials to improve outcomes. NEW Comment—#LongCOVID: aiming for a consensus.
2
46
90
NEW Viewpoint—A2BCD: a concise guide for #asthma management. From Prof Marek Lommatzsch & colleagues
0
42
94
NEW Series—Interleukin-6 receptor blockade in patients with #COVID19: placing clinical trials into context. From Federico Angriman & colleagues
0
46
91
Anti-inflammatory effects of roflumilast in #COPD (ROBERT): a 16-week, randomised, placebo-controlled trial Register now for free @LancetRespirMed & @TheLancet content from #ERSCongress
5
36
84
#Influenza100: read a selection of @TheLancet journals’ most highly cited #influenza articles and stay connected with us to receive updates and #flu content #pandemicflu #1918flu #influenza1918
1
30
77
NEW— <1/4 of #COVID19 cases shed infectious virus before symptom onset; after a 5-day self-isolation period from symptom onset, 2/3 of cases would still be infectious, but with reduced infectious viral shedding. Study from Seran Hakki & co
2
44
84
NEW—Baricitinib did not improve the composite primary endpoint of progression to NIV,.high-flow O2, IMV, or death; however, it did reduce 28-day all-cause mortality by 38·2% vs placebo (HR 0·57 [95% CI 0·41–0·78]). Read the COV-BARRIER study: #ISICEM2021.
2
44
80
NEW Research—Anakinra did not improve outcomes in patients with mild-to-moderate #COVID19 pneumonia. CORIMUNO-ANA-1 trial from Xavier Mariette & colleagues.
1
58
81
NEW research—Morphine for treatment of #cough in #IdiopathicPulmonaryFibrosis (PACIFY COUGH). From Philip L Molyneaux & colleagues:
3
41
85
A new individual participant data #MetaAnalysis assesses treatments for people with isoniazid-resistant #TB. #WorldTBDay #LancetTB @mcgillu
0
14
78
Our April issue is #tuberculosis theme for #WorldTBDay. Read about the latest developments in #TB and progress towards #EndTB #LancetTB.
0
18
70
NEW Research—Cumulative exposure to higher intensities of #mechanicalventilation was harmful, even for short durations. Prospective cohort study from Eddy Fan & colleagues on time-varying intensity of mechanical ventilation and mortality
1
39
76
Linked Comment—Awake prone positioning in #COVID19: is tummy time ready for prime time?. From Jason Weatherald & colleagues . On the meta-trial
3
32
73
James Chalmers and Sanjay H Chotirmall propose a reassessment of the current approach to #bronchiectasis in this Series … @dundeeuni @NTUsg
2
30
75
NEW—Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation. From the @PHOSP_COVID Collaborative Group #longCOVID @REvans_Breathe @LouiseVwain
3
51
75
On #WorldPneumoniaDay, ICYMI our news piece from earlier this year on the @resinstudy report Sizing Up Pneumonia Research highlighted the lack of funding for #pneumonia @PneumoniaDay #StopPneumonia #WPD2018
0
18
65
New Spotlight on #COVID19 infection in children from Dr Ian P Sinha and colleagues . Includes info on a national guideline for management of children with #COVID19 from.@RCPCHtweets.
0
39
67
NEW Research—In suspected #COVID19 in the community, doxycycline was not associated with clinically meaningful reductions in time to recovery or hospital admissions or deaths, and should not be used as a routine treatment . Read the PRINCIPLE trial here
3
37
71
NEW Comment—#SARSCoV2 antigen testing: weighing the false positives against the costs of failing to control transmission. From Elizabeth Fearon & colleagues
0
35
68
NEW Research—A single dose of the FINLAY-FR-1A vaccine against #SARSCoV2 strengthened the pre-existing natural immunity, with excellent safety profile. RCT from @OchoaAzze & colleagues
1
40
67
NEWS: Omicron variant and booster COVID-19 vaccines
14
43
65
NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval. Study from Prof Sander & co
3
37
64
NEW Personal View—Confronting #COVID19-associated #cough and the #postCOVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. From Prof Kian Fan Chung and colleagues
0
35
69
#Lymphopenia is a common feature of #COVID19 and might be a critical factor associated with disease severity and mortality.
3
35
56
NEW Spotlight—Why has the incidence of #tuberculosis not reduced in London during the #COVID19 pandemic?. From @danlewer & colleagues
3
38
62
The field of #pulmonaryhypertension has been transformed by advances in understanding of pathophysiological mechanisms and the development of a wide range of #therapeutic options. Find out more in a new @LancetRespirMed Series #PH #PAH #CTEPH #COPD #ILD
4
30
66
NEW Series paper—Understanding clinical and biological heterogeneity to advance precision medicine in #PARDS. From @Martin_Kneyber & colleagues: The third in a Series of papers from @TheLancet and @LancetRespirMed on #ARDS
2
22
64
"Lung damage from bronchiectasis is irreversible and treatment options are scarce. Until recently, most trials have been negative.". Read our Editorial on #bronchiectasis here:
2
27
66
Call for papers - we're seeking high quality studies in the field of cystic fibrosis. Submit your research here: #CysticFibrosis
3
33
58
The December issue of @LancetRespirMed is now online! . Access it here: #COVID19, #ILD, #ecigerettes, and more.
1
25
60
NEW Research—Point-of-care serological assays for delayed #SARSCoV2 case identification among health-care workers in the UK . From Capt Scott J C Pallett & colleagues
1
29
58
Our NEW MAY ISSUE is here: including content on #COPD, primary ciliary dyskinesia, prematurity-associated lung disease, and much more! . Check it out here:
1
38
58
Duet of papers: microbiome and respiratory disease/critical illness
0
69
53
NEW—Updated, long-term data from the CROWN study show durable benefit of lorlatinib vs crizotinib in pts w/ treatment-naive, ALK-positive #NSCLC. From Prof Benjamin Solomon & colleagues
4
34
59
Interesting podcast on #pleural disease from @ERSpublications Read our Review on #malignant #pleural #effusion management: keeping the flood gates shut by .Prof Najib M Rahman and colleagues here
0
30
56
NEW Research—#Tocilizumab is not an effective therapeutic option for adults with #COVID19, although there might be a role for it in adults with severe #COVID19 in India. From Arvinder Soin & colleagues With accompanying podcast:
0
31
58
The first issue of @LancetRespirMed for 2021 is here Includes original research on #RSV, #asthma, pulmonary embolism, #IPF, and systemic sclerosis-ILD, and much much more!
0
16
57
Home oxygen probably makes little or no difference to 3-year mortality in pts with #COPD and moderate hypoxaemia. Systematic review & meta-analysis from Yves Lacasse & colleagues
2
27
57
NEW Comment—Association of SARS-CoV-2 infection and persistence with #longCOVID. From Scott J Tebbutt & colleagues
1
33
54
Comment: Deep learning and the evaluation of #pulmonary fibrosis Register now for free @LancetRespirMed & @TheLancet content from #ERSCongress
0
27
52
CORRESPONDENCE: Effectiveness of COVID-19 vaccines to prevent #longCOVID: data from Norway. Data demonstrate real-world effectiveness of COVID-19 vaccines to prevent long COVID symptoms and post-COVID thromboembolic and cardiovascular complications .
1
30
54
NEW Podcast—On the STOIC trial of budesonide for early #COVID19, with Mona Bafadhel . PODCAST: STUDY:
4
27
52
NEW Research—@ISARIC4C Deterioration model for adults hospitalised with #COVID19 can predict clinical deterioration and inform decision making . From Rishi Gupta and colleagues @CCPUKstudy @ucl
1
29
52
A stay in the #ICU can have long-lasting physical and psychological consequences. This month’s cover story is about the InS:PIRE programme in Glasgow, which helps people to get back on their feet after #CriticalCare. @GRIICUQI @taraquasim
3
43
47
NEW Research—Early mobilisation might improve long-term cognitive impairment in ICU survivors after MV, but the increased risk of adverse events in the intervention group should be noted . Read the RCT from Bhakti Patel & colleagues here: . #SCCM2023
2
26
50
NEW Research—Sleep disturbance after hospitalisation for #COVID19 is associated w/ dyspnoea, anxiety, & muscle weakness. Targeting sleep disturbance might be beneficial in treating the #postCOVID19condition. From Callum Jackson & colleagues #ECCMID
0
19
48
Attending @ERSTalk #ERSCongress in Paris? You are invited to join our Editor Emma Grainger and a panel of experts to discuss new insights in diagnosis and treatment of #bronchiectasis Read a new Series with @TheLancet
0
26
49
Three-quarters of COPD cases are linked to childhood risk factors that are exacerbated in adulthood - new research #COPD #asthma @unimelb @MonashUni
0
67
50
The final issue of @LancetRespirMed for 2020 is live! . Includes original #COVID19 research:.1) COVID-19 in UK homeless population.2) Pathophysiology of COVID-19-associated #ARDS. And much, much more
1
20
48